Tweets
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Novartis. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Patients with elevated IL-6 baseline levels had greater response to sarilumab compared with MTX or adalimumab. #L08 https://t.co/uxMOSD2B1E @RheumNow #ACR18
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
7 years 9 months ago
Possible efficacy with LEF/HCQ in primary SS. #L10 https://t.co/1BKglr3JSF @RheumNow #ACR18
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
7 years 9 months ago
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Horizon Pharma. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
IXE efficacious in r-axSpA at Week 16 in TNF failure pts. #L12 https://t.co/MCpXDj9Z2o @RheumNow #ACR18
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
7 years 9 months ago
SEC shows efficacy in AS over 5 years. #L13 https://t.co/JQFdYlA3ku @RheumNow #ACR18
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
7 years 9 months ago
US can be used to reliably identify structural and inflammatory changes in knee OA – often earlier or better than plain radiography. https://t.co/MSp2QlqSFP @RheumNow #ACR18 #2909
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
7 years 9 months ago
RheumNow expanded twitter coverage of the ACR 2018 Annual meeting sponsored in part by Eli Lilly and Company. All content chosen and distributed by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
Final presentation of #ACR18 - Marissa Lassere presenting #ARAD data on opioid use in Australians with inflammatory arthritis. Use of high-potency opioids more likely in socioeconomically disadvantaged RA patients.
#SDOH
@RheumNow
ǝlʇʇıɥʍ ɯɐs @samwhittle ( View Tweet )
7 years 9 months ago
Bimekizimab phase 2 presented at #ACR18 with extremely impressive results for joints and skin improvement (in fact the primary outcome was ACR50!!!).... game changer? @RheumNow https://t.co/3lKkIMiSCI
Arthur Lau @ArthurRheum ( View Tweet )
7 years 9 months ago
Pooled analysis from 3 PSA+12 PSO trials on ixekizumab RCTs. Reassuring that incidence of IBD relatively low with significant pt year f/u (https://t.co/icWfGIEnxt @RheumNow #ACR18
Arthur Lau @ArthurRheum ( View Tweet )
7 years 9 months ago
Now available: https://t.co/QrHTupEmaN. #acr18 https://t.co/N7dWlp3zz2
Dr. John Cush @RheumNow ( View Tweet )
7 years 9 months ago
SEAM PSA study: wow MTX monotherapy was surprisingly good for ACR scores (ETN clearly better especially for high bar outcomes, but not too shabby at all for MTX mono)
https://t.co/dc2vYFs8pY @RheumNow #ACR18
Arthur Lau @ArthurRheum ( View Tweet )
7 years 9 months ago
ETN plus MTX combo better for skin PSO outcomes, but not a huge improvement for joints... but remember this study used ETN 50 q week (not twice weekly like used for PSO) @RheumNow
Arthur Lau @ArthurRheum ( View Tweet )
7 years 9 months ago
LB abstract L06: Genovese et al. Filgotinib (JAK1-i) for treatment of RA after biologic failure. ACR 20/50/70 = 70/46/32% by 24 weeks. No GI perforations seen. #ACR18 @RheumNow https://t.co/5rAqz7ljXO
Suleman Bhana, MD @DrBhana ( View Tweet )
7 years 9 months ago
